BioSpace News Archive

During the second quarter 2023 Halberd continued its groundbreaking work on its path to creating new technology products and safe, yet effective treatments for previously considered incurable or difficult-to-treat diseases.

Avinger, Inc. today announced that it will release its financial results for the second quarter 2023 after the close of trading on Thursday, July 27, 2023.

NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (“NurExone” or the “Company”) is pleased to announce significant advancements in extracellular vesicles (EVs) functionality. Leveraging its proprietary and patented 3D-Flow production, the Company has achieved significantly enhanced EV functionality.

BKG Medical Supplies, a global sourcing, supply chain and logistics medical products company has been awarded a national group purchasing agreement from Premier, Inc. for the supply of the TrueClr external urinary catheter product line.

Sangamo Therapeutics, Inc. today announced they have entered into a research evaluation, option and license agreement to develop epigenetic medicines leveraging zinc finger proteins (ZFPs) for sequence-specific DNA recognition.

Twist Bioscience Corporation today announced that it will issue its financial results for the fiscal 2023 third quarter ended June 30, 2023, before the opening of the market on Friday, August 4, 2023.

Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q) (the Company), the Company developing a new class of synthetic anti-infectives, today announced positive results from a Phase I (R327-001) study of RECCE® 327 (R327) as an intravenous (IV) infusion formulation in 80 healthy male subjects.

Vericel Corporation today announced that it will report its second-quarter 2023 financial results on Wednesday, August 2, 2023.

Artivion, Inc. announced today that second quarter 2023 financial results will be released on Thursday, August 3, 2023 after the market closes.

Schrödinger, Inc. today reported that on July 14, 2023, the company granted (i) non-statutory stock options to purchase 10,250 shares of the company’s common stock to nine newly hired employees and (ii) restricted stock units (RSUs) with respect to 6,225 shares of the company’s common stock to nine newly hired employees.